Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
879.00
Value Traded
-
Short % Float
0.7%
Days to Cover
2.1
+0.1%Week
+0.2%1 Month
+1.12%3 Month
+1.31%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
147.19 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
146.73 M
Total Shares
14.79 M
Float Shares
11.43 M
Insiders
22.76%
Institutions
6.62%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ALPX Catalyst Timeline
Dated clinical, regulatory and corporate events for Alopexx, Inc.
Past FDA Catalysts and PDUFA Decisions
How ALPX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ALPX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hugreat Ltd10% Owner | Buy | 187,500 187,500 held | $0.00 | 06/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALPX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ALPX for Q2 2026. | ||||
ALPX Institutional Ownership Trends
ALPX Short Interest
Shares sold short, counted twice a month.
0.7%
Short % of Float
of tradable shares sold short
80.5K
Shares Sold Short
+62,290.7% vs prior count
2.1 Moderate
Days to Cover
trading days of normal volume to buy every short share back
38.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALPX ranks across every disease it competes in
Competitive Position is a premium feature
See how ALPX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALPX News
About Alopexx, Inc.
Headquarters300 DELAWARE AVE. SUITE 210 #494, WILMINGTON, DE, 19801
BIOPHARMAWATCH ELITE PLUS
Trade the next ALPX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime